Global Thyroid Gland Disorder Treatment Market 2024-2028

Global Thyroid Gland Disorder Treatment Market 2024-2028

The thyroid gland disorder treatment market is forecasted to grow by USD 848.5 mn during 2023-2028, accelerating at a CAGR of 5.01% during the forecast period. The report on the thyroid gland disorder treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rise in thyroid treatment awareness programs globally, increasing demand for levothyroxine, and growing patient population with iodine deficiency.

Technavio's thyroid gland disorder treatment market is segmented as below:

By Type

• Hypothyroidism
• Hyperthyroidism

By Distribution Channel

• Offline
• Online

By Geography

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the rising focus on emerging economies as one of the prime reasons driving the thyroid gland disorder treatment market growth during the next few years. Also, increased outsourcing of non-core activities and growing focus on natural drugs will lead to sizable demand in the market.

The report on the thyroid gland disorder treatment market covers the following areas:

• Thyroid gland disorder treatment market sizing
• Thyroid gland disorder treatment market forecast
• Thyroid gland disorder treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading thyroid gland disorder treatment market vendors that include Abbott Laboratories, AbbVie Inc., Alvogen Iceland ehf, Amgen Inc., Exelixis Inc., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, IBSA Institute Biochimique SA, JEROME STEVENS PHARMACEUTICALS INC., Lannett Co. Inc., Lupin Ltd., Mayne Pharma Group Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Piramal Enterprises Ltd., RLC Labs Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and Viatris Inc.. Also, the thyroid gland disorder treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.